Patents by Inventor Jack L. Erion

Jack L. Erion has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7015306
    Abstract: Peptide analogs of neurotensin are disclosed which are resistant to enzymatic degradation and which retain high binding affinity for neurotensin receptors. Pharmaceutical compositions of these compounds are useful for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: March 21, 2006
    Assignee: BioSynthema, Inc.
    Inventors: Ananthachari Srinivasan, Jack L. Erion, Michelle A. Schmidt
  • Publication number: 20040106548
    Abstract: Conformational constraints in diagnostic and therapeutic agents in peptides have been introduced by utilization of disulfide bonds and amide cyclizations. These constraints are responsible for altering the stability and specificity of these receptor-targeted agents. Conformationally constrained peptides containing secondary and primary amines, ethers, thioethers, amidines, esters and other functionalities have been synthesized. Methods are disclosed which incorporate multiple features of the above functionalities in the macrocyclic ring of the peptides.
    Type: Application
    Filed: July 11, 2003
    Publication date: June 3, 2004
    Inventors: Michelle A Schmidt, Jack L Erion, Ananthachari Srinivasan
  • Patent number: 5830431
    Abstract: This invention relates to radiolabeled peptide compositions for radiopharmaceutical use and, more specifically, to radiolabeled peptides for diagnostic or therapeutic use having an unmodified carboxy terminal amino acid. The radiopharmaceutical composition may be used for targeting a selected biological site. The radiolabeled peptide is characterized by having its carboxy terminal amino acid in its carboxylic acid form and the peptide is coupled to a diagnostic or therapeutic radionuclide by a chelating agent. The radiopharmaceutical composition preferably comprises a radiolabeled peptide selected from the group consisting of somatostatin, an analog of somatostatin, a derivative of somatostatin and peptides capable of binding to the somatostatin receptor, where the peptide is coupled to a diagnostic or therapeutic radionuclide by a chelating agent has its carboxy terminal amino acid in its carboxylic acid form.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 3, 1998
    Assignee: Mallinckrodt Medical, Inc.
    Inventors: Ananthachari Srinivasan, Mary Marmion Dyszlewski, Joseph E. Bugaj, Jack L. Erion
  • Patent number: 4933286
    Abstract: An isoenzyme from tomato, acid phosphatase-1 isoenzyme (Apase-1.sup.1), has ben purified to homogeneity and is subjected to amino acid sequencing and used to prepare anti-Apase-1 antibodies. The amino acid sequence permits design of probes to recover Apase-1.sup.1 -encoding cDNA; the antibodies are also useful for this purpose. The cDNA is useful to recover the genomic DNA encoding Apase-1.sup.1, which can then be used in walking or jumping techniques to recover the genomic DNA which confers nematode resistance, since this DNA resides immediately adjacent to the Apase-1.sup.1 gene on chromosome 6 of Lycopersicon esculentum.
    Type: Grant
    Filed: March 30, 1987
    Date of Patent: June 12, 1990
    Assignee: Plant Cell Research Institute, Inc.
    Inventors: Elizabeth M. Paul, Valerie M. Williamson, Jack L. Erion, Candace G. Poutre